Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3BCHECHRM1CHRM2CHRM3CHRM4CHRNA3CHRNA4CHRNB2CHRNB4ESR1ESR2GABRA1GABRB1GABRG2GBA1GHSRHRH1HTR1DHTR2AMAOBOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8UGCGrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL223358 | 0.96 | TSHR (0.47) | LMNATSHRCA4CYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL11578822 | 0.92 | LMNA (0.48) | LMNATSHRCA4CYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL9551431 | 0.92 | LMNA (0.48) | LMNATSHRCA4CYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL3160195 | 0.92 | LMNA (0.48) | LMNATSHRCA4CYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL9551433 | 0.92 | LMNA (0.48) | LMNATSHRCA4CYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL3160181 | 0.92 | LMNA (0.48) | LMNATSHRCA4CYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL11578827 | 0.92 | LMNA (0.48) | LMNATSHRCA4CYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL5961174 | 0.92 | LMNA (0.48) | LMNATSHRCA4CYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL1938734 | 0.92 | LMNA (0.48) | LMNATSHRCA4CYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL2376153 | 0.92 | LMNA (0.48) | LMNATSHRCA4CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0895809-B1 | Process Using Niobium-containing Aqueous Solution in Producing Niobium-containing Oxide Catalyst | ASAHI CHEMICAL IND (JP) | 2014-03-19 | — | — | EP | disclosed |
| CN-1216847-C | Method for preparing acrylic acid from propane under the condition of free-dioxygen | ATOPHINA CO (FR) | 2005-08-31 | — | — | CN | disclosed |
| US-6833474-B2 | Process for manufacturing acrylic acid from propane in the absence of molecular oxygen | ARKEMA (FR) | 2004-12-21 | — | — | US | disclosed |
| US-20040147393-A1 | Preparation of a multimetal oxide composition | BASF AKIENGESELLSCHAFT (DE) | 2004-07-29 | — | — | US | disclosed |
| US-20030088124-A1 | Process for manufacturing acrylic acid from propane in the absence of molecular oxygen | ATOFINA (FR) | 2003-05-08 | — | — | US | disclosed |
| CN-1375487-A | Method for preparing acrylic acid from propane under the condition of free-dioxygen | ATOPHINA CO (FR) | 2002-10-23 | — | — | CN | disclosed |
| US-6036880-A | AQUEOUS SOLUTION OF DICARBOXYLIC ACID, AN NB COMPOUND AND OPTIONALLY AMMONIA, WITH SPECIFIC DICARBOXYLIC ACID/NB MOLAR RATIO; CATALYST FOR OXIDATION OR AMMOXIDATION OR PROPANE OR ISOBUTANE TO (METH)ACRYLIC ACID OR (METH)ACRYLONITRILE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0895809-A1 | Niobium-containing aqueous solution for use in producing niobium-containing oxide catalyst | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1999-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147393-A1 | Preparation of a multimetal oxide composition | SOD1, SOD3, POLM | LMNA 1294/4885TSHR 4238/4885CA4 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.